NASDAQ · CATB
Healthcare · Biotechnology
$8.54
Down-$0.64 (-6.97%)
Updated Aug 23, 2026, 9:23 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CATB does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CATB.
CATB research
Company profile and research snapshot.
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 2, 2021 | Wedbush | Outperform | — |
| Aug 25, 2021 | HC Wainwright & Co. | Buy | — |
| May 12, 2021 | Ladenburg Thalmann | Buy | — |
| Mar 11, 2021 | Oppenheimer | Outperform | — |
| Nov 2, 2020 | Wedbush | Neutral | — |
No generated briefing is available yet.
Seeking Alpha · Jun 30, 2021
After edasalonexent's failure last year, Catabasis Pharmaceuticals pivoted to the HAE market through the acquisition of Quellis Biosciences.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CATB.
No results
No recent SID articles mention CATB.
